A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Inclusion criteria:

• Signed and dated written informed consent.

• Clinically stable outpatients who have been diagnosed with schizophrenia (as perDiagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)).

• Patients, who completed participation in the parent trial.

• Women of childbearing potential must use highly effective methods of birth control.

• Have a study partner who interacts with the patient on a regular basis. Furtherinclusion criteria apply.

Exclusion criteria:

• Participant who developed DSM-5 diagnosis other than Schizophrenia or any conditionthat would prevent the patient from participating in the extension trial sinceenrolment into the parent phase III trial.

• Any suicidal behavior and/or suicidal ideation of type 5 based on the ColumbiaSuicidality Severity Rating Scale (C-SSRS) in parent trial and up to and includingVisit 1 of this study.

• Positive urine drug screen ≥ 3 times during the treatment period of parent trial.

• Patients who are currently or wish to participate in another investigational drugtrial.

• Any clinically significant finding or condition in the judgment of the investigatorthat would jeopardize the patient´s safety while participating in the trial or theircapability to participate in the trial.

Further exclusion criteria apply.